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Summary
Objective: Micro-computed tomography (microCT) imaging has the potential to allow the three-dimensional (3D) visualization of cartilage mor-
phology. However, cartilage intensity on a microCT image is weak because cartilage does not strongly attenuate X-rays. This work was de-
signed to demonstrate that exposure of cartilage to charged gadolinium compounds modiﬁes the intensity to allow an improved visualization of
cartilage morphology and the determination of proteoglycan content.
Design: Trypsin was used to deplete proteoglycan in bovine nasal cartilage disks. Disks were then exposed to Gd3C, gadopentetate
(GdeDTPA2), or gadoteridol (GdeHPeDO3A), and imaged with microCT. The intensities of the disks were measured from the images
and compared to the actual proteoglycan content determined with a dimethylmethylene blue assay.
Results: Treatment of naı¨ve disks with 200 mM Gd3C for 24 h at room temperature produced a 2.8-fold increase in intensity on microCT im-
ages. Similar treatment with 200 mM GdeDTPA2 produced a 1.4-fold increase. After 2 h of trypsin treatment at room temperature, the in-
tensities of cartilage disks exposed to 200 mM Gd3C decreased by 12%. Conversely, the intensities of trypsin-treated disks exposed to
200 mM GdeDPTA2 increased by 15%. Trypsin treatment caused a 4% increase in the intensities of disks exposed to neutral GdeHPe
DO3A. The correlation between proteoglycan content and the microCT intensity of cartilage treated with Gd3C was very good (r2Z 0.81).
Conclusions: Gadolinium and microCT allow an improved 3D visualization of cartilage and quantiﬁcation of its proteoglycan content.
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Micro-computed tomography (microCT) is a relatively new
imaging modality that has the spatial resolution to visualize
and quantify morphology in small animal joints. The ﬁrst
generation of commercially available instruments was de-
signed for studies of ex vivo samples such as bone biop-
sies1. However, second generation instruments are
capable of obtaining images from living rodents with high
spatial resolution in reasonable image acquisition times2.
Most microCT studies thus far have focused on bone3. Re-
ports of quantitative microCT imaging of cartilage have not
appeared, possibly because the inherent intensity of carti-
lage in a microCT image is weak. Therefore, a means to im-
prove the visualization of cartilage is very desirable.
One possibility for improving cartilage visualization with
microCT can be discerned from the magnetic resonance im-
aging (MRI) literature. In 1992, Kusaka et al.4 used MRI to
show that the uptake of manganese (as Mn2C) or gadoli-
nium (as gadopentetate (GdeDTPA2)) in cartilage is asso-
ciated with the proteoglycan distribution. Since these two
ions are paramagnetic, they alter the appearance of
*Address correspondence and reprint requests to: Michael
D. Cockman, Ph.D., Eli Lilly and Company; Lilly Research
Laboratories, 2001 West Main Street, Greenﬁeld, IN 46140, USA.
Tel: 1-317-651-7239; Fax: 1-317-277-0173; E-mail: cockman_
michael_dane@lilly.com
Received 27 May 2004; revision accepted 23 August 2005.210cartilage on MRI. Subsequently, other scientists investigated
this phenomenon more thoroughly. Many efforts were fo-
cused on GdeDTPA2 because it is not toxic at doses
effective for MRI and is easily obtained as the active ingre-
dient in the commercially available contrast agent called
Magnevist. In a seminal article published in 1996, Bashir
et al.5 showed that GdeDTPA2 is taken up in cartilage in
inverse concentration to the proteoglycan content. Laurent
et al.6 extended this work by showing that GdeDTPA2
and MRI could measure proteoglycan depletion induced
by papain in the rabbit knee.
While the paramagnetism of gadolinium makes it useful
for MRI, the metal is also known to attenuate X-rays. In
fact, commercially available MRI contrast agents containing
gadolinium, such as Magnevist and Gadovist, were in-
vestigated as contrast agents for X-ray CT7,8. However,
these studies did not address the application of contrast
agents for CT of cartilage. We hypothesized that gadolinium
exposure would enhance the appearance of cartilage on mi-
croCT images and allow improved visualization. Further-
more, the uptake of gadolinium would reﬂect the
proteoglycan distribution and could be quantiﬁed from
microCT images.
Method
All images were acquired with a Scanco microCT-40
X-ray tomograph (Scanco Medical, Inc., Bassersdorf,
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a 200 ms integration time. For each slice, 250 projections
were acquired and reconstructed in a 1024! 1024 matrix;
the ﬁeld-of-view was 16.4 mm and the voxel size was
20 mm isotropic. Bovine nasal cartilage disks, 6 mm diame-
ter by 1 mm thick, were stored in Dulbecco’s modiﬁed
Eagle’s medium at 20(C until the preparation for microCT.
Proteoglycan depletion was produced using porcine trypsin
solution (25 mg/ml; SigmaeAldrich, St. Louis, MO). This
was frozen at 20(C until needed, then warmed to 4(C
overnight, then to room temperature (22(C) over the follow-
ing day. Gd3C, GdeDTPA2 or gadoteridol (Gde
HPeDO3A) solution was prepared by diluting GdCl3 (Sig-
maeAldrich),Magnevist (Berlex,Wayne,NJ) or ProHance
(Bracco, Milan, Italy), respectively, in 0.9% w/v saline
(Baxter, Deerﬁeld, IL). All solutions were maintained at
room temperature.
DEMONSTRATION OF THE CONCEPT AND OPTIMIZATION
OF THE GADOLINIUM CONCENTRATION
The primary goal of this part was to demonstrate the ef-
fect of proteoglycan depletion on the distribution of Gd3C
or GdeDTPA2 in cartilage. A secondary goal was to deter-
mine a practical working concentration of gadolinium for fu-
ture studies.
Thirteen groups of cartilage disks were prepared for mi-
croCT. Disks were thawed overnight at 4(C. Next, disks
were pretreated by soaking in saline or trypsin solution for
24 h at room temperature with occasional swirling. Twelve
groups of three or more disks were produced by removal
from the pretreatment solutions and immediately transfer-
ring to solutions of one of three concentrations of Gd3C or
GdeDTPA2 (50 mM, 100 mM, and 200 mM). One addi-
tional group was transferred to fresh saline. All disks were
soaked for an additional 24 h at room temperature.
In preparation for microCT, each cartilage disk was
removed from solution, blotted, and placed in a sample
holder. A single slice through the middle of the disk was
acquired. The mean intensity of each cartilage disk was
measured using the Scanco Ximage software. An in-
creased intensity meant that more X-ray attenuation was
occurring and therefore more gadolinium was present. In-
tensities from three disks were obtained and averaged for
each group.
COMPARISON OF PROTEOGLYCAN CONTENT
AND MICROCT INTENSITY
This work was conducted to determine the relationship
between the proteoglycan contents of cartilage disks and
their intensities in microCT images. A second goal was to
demonstrate that the charge of the gadolinium complex af-
fects its uptake in cartilage.
For this work, the trypsin solution was diluted to 0.25 mg/
ml in 0.9% w/v saline (Baxter) to allow more control over
proteoglycan loss. The cartilage disks were thawed at
22(C for 80 min, and then refrigerated at 4(C for nearly 3
days. The disks were then placed in a hood for 1 h to equil-
ibrate at room temperature (w22(C). Disks were pretreated
by immersing them in the diluted trypsin solution for 0, 2, 4,
or 6 h at room temperature and ensuring good mixing with
an orbital shaker at 75 rpm. Next, groups of three pretreated
disks were immersed in 200 mM Gd3C, GdeDTPA2 or
GdeHPeDO3A solutions for 24 h, again at roomtemperature with orbital shaking. Thus, there were 12 treat-
ment groups of three disks each.
In preparation for microCT, each cartilage disk was re-
moved from the gadolinium solution, blotted, and placed
in a custom-built cell that allowed three disks to be scanned
simultaneously. A three-dimensional (3D) scan of the disks
was acquired. For each scan, a maximum of 137 slices
were acquired, covering up to a 2.83-mm thick region.
The maximum total image acquisition time was 34.5 min.
After scanning, each disk was placed in saline in a small
vial and frozen at 20(C until assessment of proteoglycan
concentration.
The mean intensity of each disk was quantiﬁed using
a custom software application written for the Aphelion plat-
form (ADCIS, Caen, France). The algorithm consisted of the
following steps:
(1) Read in the 16-bit 3D dataset.
(2) Make a two-dimensional (2D) MAX image that is the
maximum of all slices.
(3) Threshold the MAX image to ﬁnd the outline of each
individual cartilage disk.
(4) Threshold each image, and then identify and obtain
a count of voxels belonging to each cartilage disk.
(5) Gather detected voxel intensity information to calcu-
late the total, average, and standard deviation of all inten-
sities within each cartilage disk.
(6) Calculate the mean and standard deviation of the av-
erage intensities of all cartilage disks for each treatment
group.
The proteoglycan content of each cartilage disk was
quantiﬁed using a modiﬁcation of the dimethylmethylene
blue assay as described by Farndale et al.9. A 20 mM
sodium phosphate buffer was adjusted to pH 6.8 with phos-
phoric acid. Next, 1 mM ethylenediamine tetraacetic acid
(Mallinckrodt Baker, Phillipsburg, NJ) and 2 mM dithiothrei-
tol (SigmaeAldrich) were added, followed by the addition of
a papain suspension (SigmaeAldrich) to produce a concen-
tration of 3 mg/ml papain. Each disk was digested in 3 ml of
the papain-containing phosphate buffer by heating between
50 and 60(C for a minimum of 3 h. The digest was centri-
fuged to produce a supernatant. Two hundred ﬁfty microli-
ters of supernatant was diluted in 1 ml of a 9.295 mg/ml
iodoacetic acid (SigmaeAldrich) solution, 750 ml phosphate
digestion buffer, and 3 ml of a 50 mM Tris/HCl (Sigmae
Aldrich) pH 8 buffer. Standards were made by dissolving
chondroitin sulfate A (SigmaeAldrich) in phosphate diges-
tion buffer and iodoacetic acid solution. A color reagent
was made with dimethylmethylene blue (SigmaeAldrich).
Samples of the standard solutions and triplicates of the
supernatant solution from each disk were pipetted onto
a 96-well plate and the color reagent was added to each.
Then the optical density at 525 nm was determined for
each well with an UV/Vis spectrophotometer (SpectraMax
Plus, Molecular Devices, Sunnyvale, CA).
Statistical comparisons of group means were performed
using the one-way analysis of variance (JMP statistical
analysis software, version 4.0.4, SAS Institute, Inc., Cary,
NC). Signiﬁcance was established at P! 0.05.
Results
Figure 1 consists of representative microCT images of
cartilage disks that show the effects of treatment with
Gd3C or GdeDTPA2. In the absence of gadolinium,
212 M. D. Cockman et al.: MicroCT of cartilageFig. 1. MicroCT images of bovine nasal cartilage disks treated with saline or trypsin followed by Gd3C or GdeDTPA2 exposure. Trypsin re-
moves negatively charged proteoglycans causing reduced electrostatic attraction of Gd3C (darkening) or reduced electrostatic repulsion of
GdeDTPA2 (brightening). (a) Saline, day 1; 100 mM Gd3C, day 2; (b) saline, day 1; 200 mM GdeDPTA2, day 2; (c) trypsin, day 1;
100 mM Gd3C, day 2; (d) trypsin, day 1; 200 mM GdeDTPA2, day 2.saline-treated cartilage appeared dark gray (not shown). In
disks treated with saline on day 1, Gd3C was taken up,
causing brightening [Fig. 1(a)], whereas GdeDTPA2 was
largely repelled and the cartilage remained dark
[Fig. 1(b)]. When disks were treated with trypsin, the proteo-
glycans were removed. Therefore, Gd3C was not taken up
as much and the cartilage was darker than when it was
saline-treated [Fig. 1(c)]. On the other hand, removal of pro-
teoglycans meant that more GdeDTPA2 could enter a
cartilage disk and it appeared brighter than a saline-treated
disk [Fig. 1(d)].
Figure 2 shows the change in intensity with Gd3C concen-
tration for cartilage disks pretreated for 24 h with saline or
trypsin solution. In cartilage pretreated with saline,
increasing [Gd3C] increased the cartilage intensity. This
behavior ﬁt a rising exponential curve (intensityZ 2320C
4188! (1 exp(0.019! [Gd3C])), r2Z 0.994). In partic-
ular, the intensity of cartilage treated with 200 mM Gd3C
was 2.8-fold greater than that of naı¨ve cartilage. In
trypsin-treated disks, increasing [Gd3C] also increased
the cartilage intensity. This ﬁt a linear function
(intensityZ 2668C 10.95! [Gd3C], r2Z 0.999).
Figure 3 shows analogous results for GdeDTPA2. In-
creasing GdeDTPA2 concentration also increased carti-
lage intensity but to a lesser degree than Gd3C.
In cartilage pretreated with saline, increasing [GdeDTPA2]increased the cartilage intensity linearly (in-
tensityZ 2231C 4.78! [GdeDTPA2], r2Z 0.963). The
intensity of cartilage treated with 200 mM GdeDTPA2
was 1.4-fold greater than that of naı¨ve cartilage. When
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Fig. 2. Uptake of three concentrations of Gd3C in bovine nasal car-
tilage disks after pretreatment with saline or trypsin.
213Osteoarthritis and Cartilage Vol. 14, No. 3proteoglycans were depleted with trypsin pretreatment, in-
creasing [GdeDTPA2] also produced a linear response,
but the slope was much greater (intensityZ
2146C 12.01! [GdeDTPA2], r2Z 0.999).
Figure 4 shows the dynamics of degradation of the carti-
lage disks with dilute trypsin as determined by the measure-
ments of average intensity on microCT images. In those
disks treated with Gd3C, the intensity of the disks de-
creased with continued exposure to dilute trypsin, consis-
tent with the hypothesis that the amount of Gd3C present
was proportional to the amount of negatively charged pro-
teoglycans. In this study, the degradation appeared to be bi-
phasic with a signiﬁcantw12% decline in intensity over the
ﬁrst 2 h of dilute trypsin exposure, followed by a 2-h plateau,
and then by an additional signiﬁcant w4% loss of intensity
over the ﬁnal 2 h. Disks treated with the neutral agent,
GdeHPeDO3A, showed a slight, but signiﬁcant w4%
increase in intensity over the ﬁrst 2 h of exposure to
dilute trypsin, possibly due to diffusion of the solution,
rather than electrostatic attraction. Disks treated with
Uptake of Gd-DTPA2- in bovine nasal cartilage
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Fig. 3. Uptake of three concentrations of GdeDTPA2 in bovine na-
sal cartilage disks after pretreatment with saline or trypsin.
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Fig. 4. The dynamic effects of trypsin exposure on uptake of
200 mM Gd3C, 200 mM GdeDTPA2, and 200 mM GdeHPe
DO3A as determined by microCT.GdeDTPA2 behaved oppositely from those treated with
Gd3C. There was a signiﬁcant w15% intensity increase
that was maintained for the longer exposures to dilute tryp-
sin. This ﬁts the concept that more GdeDTPA2 penetrated
a cartilage disk as negatively charged proteoglycans were
removed by trypsin.
Proteoglycan was not detected in the disks treated with
dilute trypsin and GdeDTPA2 or GdeHPeDO3A. The rea-
sons for this are not clear; however, it is possible that addi-
tional degradation due to residual trypsin could have
occurred during the time prior to storage at 20(C. In con-
trast, proteoglycan was measurable in 10 of the 12 disks
treated with saline or dilute trypsin and Gd3C. (The two
disks from which proteoglycan could not be detected were
treated with dilute trypsin for 6 h.) Figure 5 shows the corre-
lation between total proteoglycan content and total microCT
intensity for 10 of the 12 samples exposed to Gd3C. The re-
lationship between the variables was very good (r2Z 0.81).
The large y-intercept was easily explained since Gd3C-trea-
ted cartilage was still visible on microCT even after proteo-
glycan depletion.
Discussion
This work shows that gadolinium can be used to improve
the appearance of cartilage in microCT images. This opens
the possibility of measuring descriptors of cartilage mor-
phology, such as thickness and volume, from microCT im-
ages. Furthermore, this work shows that there is a strong
positive association between proteoglycan content and
Gd3C concentration in cartilage (Fig. 5). Since gadolinium
attenuates X-rays, the intensity of cartilage treated with
Gd3C on microCT images reﬂects the proteoglycan content.
Therefore, microCT studies of animal models of osteoarthri-
tis, which heretofore have focused on bone10, could be
more comprehensive with the use of gadolinium treatment.
If GdeDTPA2 was completely repelled by negatively
charged proteoglycans, a change in the microCT intensity
of naı¨ve disks should not havebeenobservedwith increasing
[GdeDTPA2]. However, Fig. 3 shows that GdeDTPA2
was taken up by naı¨ve cartilage disks, albeit to a lesser
extent than Gd3C. The uptake of GdeDTPA2, especially
at the higher concentrations, indicated an incomplete
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cans; that is, there was an excess of GdeDTPA2 that
diffused into the cartilage. With proteoglycan depletion
due to trypsin treatment, there was less repulsion and
more GdeDTPA2 could penetrate the cartilage, produc-
ing the greater slope seen in Fig. 3.
In the absence of trypsin pretreatment, there were funda-
mental differences in the image intensities of cartilage disks
treated with Gd3C, GdeDTPA2, or GdeHPeDO3A solu-
tion, as shown in Fig. 4. This cannot be explained by differ-
ences in gadolinium concentration, because these were
identical for the solutions (200 mM). The duration of expo-
sure seems an unlikely reason, as well, since the cartilage
disks were soaked for 24 h with good mixing. The most likely
explanation lies in the electrostatic charge and molecular
structure of the three sources of gadolinium and their rel-
ative contributions. It was clear that the free gadolinium
ion, Gd3C, produced the greatest attenuation, most likely
due to its charge and small size.
Of the disks pretreated with diluted trypsin, only those
treated with Gd3C had sufﬁcient proteoglycan for measure-
ment with the dimethylmethylene blue assay. The disks
treated with diluted trypsin and GdeHPeDO3A or
GdeDTPA2 behaved differently. Measurable amounts of
proteoglycan were not found in any of these disks. This
may indicate that Gd3C quenches proteoglycan degrada-
tion by trypsin, whereas GdeHPeDO3A and GdeDTPA2
do not. Certainly the conditions for additional degradation
were present after removal from the trypsin solution, since
each disk was exposed to a gadolinium solution for 24 h
at room temperature, followed by microCT scanning, which
is known to warm the sample slightly during scanning.
The slope of the correlation between microCT intensity
and proteoglycan content (Fig. 5) was probably a function
of the concentration of the Gd3C solution. A steeper slope
could probably be obtained by using a greater concentration
of Gd3C. This, in turn, could increase the ability to distin-
guish between more subtle variations in proteoglycan con-
tent with microCT. However, the practicality of this would
be limited by the solubility of GdCl3.
The concentration of gadolinium needed for microCT
studies of cartilage is open for debate and is governed
by whether it is used ex vivo or in vivo. Certainly, as
the concentration increases, the X-ray attenuation in-
creases as well. This enables better visualization of carti-
lage and possibly improves the sensitivity to variations in
proteoglycan content. Therefore, based on the work re-
ported here, we have chosen a concentration of
200 mM Gd3C for our ongoing studies of excised bones.
Delivering such a concentration of Gd3C to cartilage in
vivo could be achieved by intra-articular or intravenous in-
jection. The blood volume of rodents is about 60e70 ml/
kg11. Therefore, to achieve a blood concentration of
200 mM Gd3C requires approximately 12 mmol/kg. How-
ever, this would certainly be lethal, since the intravenous
LD50 of GdCl3 is approximately 0.5 mmol/kg in mice and
rats12,13. By virtue of chelation, GdeDTPA2 is much
less toxic than Gd3C with an intravenous LD50 of about
6 mmol/kg in mice and 8e10 mmol/kg in rats13,14, but
again a 200 mM blood concentration would not be ac-
ceptable. Therefore, microCT using a gadolinium probe
will have its greatest applicability for terminal studies or
studies of excised bones.In summary, gadolinium treatment and microCT imaging
are a powerful combination for studies of small animal
bones, enabling the measurement of descriptors of bone
and cartilage morphology, as well as proteoglycan
distribution.
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